Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Visit NurExone Biologic Inc.

NurExone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons.



Bullboard - Investor Discussion Forum NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following... see more

Bullboard (TSXV:NRX)

View:
Post by Mathew177on Jun 27, 2024 12:34pm

Nurexone Accelerates Growth with Dr. Yona Geffen’s Expertise

NurExone Biologic Inc. Accelerates Growth with Dr. Yona Geffen’s Expertise (TSXV: NRX, OTCQB: NRXBF) https://10xalerts.com/nurexone-biologic-inc-accelerates-growth ...more  
Post by Jonathon Brownon Jun 27, 2024 6:56am

Buzz on the Bullboards: Updates from Nevada Copper, BlackBerry, Tilray

Post by ElliotGHon Jun 06, 2024 9:16am

NurExone Biologic Inc - LitchField Hills Research Report

NurExone Biologic Inc - LitchField Hills Research Report (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V) https://pdfhost.io/v/LyPDoUVAp_NRX_1Q24_Final
Post by Mathew177on Jun 04, 2024 9:26am

$NRX Game-Changing Moves in Biopharmaceuticals and Exosome

NurExone’s Game-Changing Moves in Biopharmaceuticals and Exosome Technology (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V) https://10xalerts.com/nurexones-game-changing ...more  
Post by Brice978on May 24, 2024 4:26pm

NurExone's Expands Commercialization Efforts with All-star H

https://10xalerts.com/nurexones-expands-commercialization-efforts-with-all-star-hire-tsxv-nrx/
Post by 88guy88on May 14, 2024 11:33am

2.5 years to break even for this company

thats a long wait for a maybe....this one is for patient speculators only.....no quick trade flip here....go try those meme stocks for a rush 34,500 shares for sale at 53 cents and only 3000 bid at ...more  
Post by 88guy88on May 13, 2024 12:09pm

Wait for 41 cents

looks like it wants to head back to the 200 day moving average which is 41 cents....no news or results for a long time while they do research now....thin trader.....good luck!
Post by 88guy88on May 03, 2024 10:03am

100,000 shares are for sale at 63 cents

only a few thousand shares on the offers in the 50s.....here we go!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.NRX



Investor Presentation

View the Presentation

Investment Opportunity

NurExone operates according to two business lines – Development of a first exosome-based therapy for acute Spinal Cord Injuries (SCI).

In parallel, the company is monetizing its proprietary ExoTherapy platform through licensing to the global biopharmaceutical industry to deliver therapies for other diseases and indications.

The company’s first product, ExoPTEN, for acute spinal cord injury, has been granted Orphan Drug Designation by the FDA.



Why NurExone??

The Ultimate Drug Delivery System

The Beginning of NurExone

Facebook

Contact Us

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com

Dr. Eva Reuter Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu